Literature DB >> 31418099

Electrophysiology devices and the regulatory approval process within the U.S. FDA and abroad.

Kimberly A Selzman1, Hetal Patel2, Kenneth Cavanaugh2.   

Abstract

Almost all electrophysiology (EP) devices need to obtain premarket approval before they can be commercially sold and available for use in the community. The US Food and Drug Administration (FDA) has different paths to market approval depending on the intended use and the associated risks of the device. The European Union and Japan have device approval processes that have many similarities as well as differences to the US regulatory system. This paper describes some of the history and background of the US device approval process with an emphasis on EP devices. It provides an overview of the different regulatory pathways in the USA that are currently being utilized and contrasts them to the procedures often used in the European Union and in Japan. It also touches on the impact of the twenty-first Century Cures Act and how the balance between premarket and postmarket regulatory oversight is continually being examined and refined.

Keywords:  Approval; De novo; Device; FDA; Premarket; Regulation

Mesh:

Year:  2019        PMID: 31418099     DOI: 10.1007/s10840-019-00607-x

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  21 in total

1.  Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study.

Authors:  Cecilia Linde; William T Abraham; Michael R Gold; Claude Daubert
Journal:  J Am Coll Cardiol       Date:  2010-11-23       Impact factor: 24.094

2.  Medical device and radiological health regulations come of age.

Authors:  Carol Rados
Journal:  FDA Consum       Date:  2006 Jan-Feb

3.  Medical device recalls: get it right the first time: Comment on "Medical device recalls and the FDA approval process".

Authors:  Rita F Redberg; Sanket S Dhruva
Journal:  Arch Intern Med       Date:  2011-02-14

4.  Global cardiovascular device innovation: Japan-USA synergies: Harmonization by Doing (HBD) program, a consortium of regulatory agencies, medical device industry, and academic institutions.

Authors:  Takahiro Uchida; Fumiaki Ikeno; Koji Ikeda; Yuka Suzuki; Koji Todaka; Hiroyoshi Yokoi; Gary Thompson; Mitchel Krucoff; Shigeru Saito
Journal:  Circ J       Date:  2013-03-29       Impact factor: 2.993

Review 5.  New technology in electrophysiology: FDA process and perspective.

Authors:  Kimberly A Selzman; Mark Fellman; Andrew Farb; Sergio de Del Castillo; Bram Zuckerman
Journal:  J Interv Card Electrophysiol       Date:  2016-03-28       Impact factor: 1.900

Review 6.  The Clinical Innovation Network: a policy for promoting development of drugs and medical devices in Japan.

Authors:  Shunsuke Matsushita; Keisuke Tachibana; Masuo Kondoh
Journal:  Drug Discov Today       Date:  2018-05-24       Impact factor: 7.851

Review 7.  Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy.

Authors:  Ron Waksman; Lakshmana K Pendyala
Journal:  Am J Cardiol       Date:  2014-11-12       Impact factor: 2.778

8.  Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.

Authors:  Vivek Y Reddy; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Petr Neuzil; Kenneth Huber; Jonathan L Halperin; David Holmes
Journal:  Circulation       Date:  2013-01-16       Impact factor: 29.690

Review 9.  New Regulatory Framework for Medical Devices in Japan: Current Regulatory Considerations Regarding Clinical Studies.

Authors:  Akihide Konishi; Soichiro Isobe; Daisaku Sato
Journal:  J Vasc Interv Radiol       Date:  2018-03-13       Impact factor: 3.464

10.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.

Authors:  David J Wilber; Carlo Pappone; Petr Neuzil; Angelo De Paola; Frank Marchlinski; Andrea Natale; Laurent Macle; Emile G Daoud; Hugh Calkins; Burr Hall; Vivek Reddy; Giuseppe Augello; Matthew R Reynolds; Chandan Vinekar; Christine Y Liu; Scott M Berry; Donald A Berry
Journal:  JAMA       Date:  2010-01-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.